⌕
Insmed · INSM · Nasdaq
Tenet 33 · Weak
Compare
$122.88+1.42%At closeTenet 33 · Weak
$122.88+1.72 (+1.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Insmed (INSM) Stock

Insmed (INSM) closed at $122.88 on Nov 16, 2026; its Tenet Score is 33 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

24 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$122.88
Nov 16, 2026
Market cap
$27.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
90.39 – 212.75
low → high · as of close, Nov 16, 2026
Tenet Score
33/100
Weak · 340 Healthcare peers

Industry: Drugs

Insmed Inc scores 33/100. Weak. Value is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
33/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
4
Quality
40
Health
40
Growth
47

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityDHealthDGrowthDMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
37.1×
Sep 30, 2026 balance sheet
P/S
17.7×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−72%
TTM through Sep 30, 2026
Operating margin
−205.6%
fiscal 2025, before interest and tax
Net margin
−39.9%
TTM through Sep 30, 2026
Current ratio
2.86
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Insmed Inc

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacte…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 187 US ETFs · top wrappers by weightSee all ETFs holding INSM →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

Compare Insmed with

What sector and industry is Insmed in?

Insmed is in the Healthcare sector and the Drugs industry.

What is Insmed's Tenet Score?

Insmed's Tenet Score is 33 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.